Blog March 23, 2020
Judicial Review Available for Decision that a Patent Qualified for CBM Review; § 101 Review Appropriate in CBM Review
- Person title
Versata Development Grp., Inc. v. SAP Am., Inc., ___F.3d ___ (Fed. Cir. July 9, 2015) (Newman, PLAGER, Hughes (dissenting in part)) (P.T.A.B.) (5 of 5 stars)
Federal Circuit affirms determination, following CBM ("covered business method") review, of invalidity under § 101, and resolves several procedural issues along the way.
Jurisdiction: Judicial review is available for a PTAB decision that a patent qualifies for CBM review. Such review is available only upon the PTAB's entry of a final written decision. Although section 324(e) makes the PTAB's institution decisions non-reviewable, it does not bar review, upon the PTAB issuing a final written decision in a CBM review, of whether the PTAB's determination that the patent qualified for CBM review in the first place. The issue was reviewable because it went to the PTAB's power to invalidate the claims.
"Covered Business Method": The PTAB correctly determined that the patent under review qualified for CBM review. The statutory definition of "covered business method patent" included within that term patents claiming techniques for "performing data processing operations...used in the practice, administration, or management of a financial product or service[.]" 35 U.S.C. § 18(d)(1). Such text was not limited to patents specifically targeting the financial services industry. Thus the '350 patent, which was directed to techniques for determining product pricing, fell within both definitions. The '350 patent also did not fall within the statutory exception provided for patents for "technological inventions." The '350 patent claims techniques of using data hierarchies to organize pricing information. "[T]his is not a technical solution but more akin to creating organizational management charts." Op. at 39.
Claim Construction: The PTAB's application of the "broadest reasonable interpretation" standard for claim interpretation was correct. The Fed Cir previously confirmed the appropriateness of this standard in the IPR context in Cuozzo, and such reasoning applies equally to the CBM context.
Availability of Section 101: The PTAB's determination that a CBM proceeding could invalidate a patent on § 101 grounds was subject to judicial review, for the reasons discussed above pertaining to judicial review of a PTAB decision that a patent qualified for CBM review.
The PTAB correctly determined that the CBM statute granted authority to apply § 101 review in CBM proceedings. The statute referred to CBM review (and post-grant review generally) of "patentability"; prior Fed Cir and Supreme Court opinions "established that § 101 challenges constitute validity and patentability challenges." Slip op. at 45.
Merits: The PTAB correctly determined that the claims were invalid under § 101. Applying the first step of Alice and Mayo, the claims were directed to the abstract idea of "determining a price, using organizational and product group hierarchies." Op. at 51. Applying the second step, the claims lack additional limitations that might transform the abstract idea into a patentable invention, as they recite using a computer in purely conventional ways to perform the various functions of the claims. None of Versata's counterarguments were persuasive. The record demonstrated that the PTAB properly considered the claims as a whole. Purported benefits of the claims (e.g., efficiency, increased computer performance) were not recited in any claim. There was no inconsistency in construing the claims to require a "computer storage medium," and then finding "that the underlying, patent-ineligible invention could be performed via pen and paper or in a person's mind." Slip Op. at 55. The PTAB properly allocated the burdens of proof.
Dissent-in-part: Judge Hughes agreed with the majority that the PTAB properly held the '350 patent claims invalid under § 101, and that the "broadest reasonable interpretation" standard is appropriate for CBM. In his view, however, the PTAB's initial determination that the patent at issue was a "covered business method patent" was not subject to judicial review.
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.
Blog November 4, 2019
Legal Alert | Arthrex, Inc. v. Smith & Nephew, Inc. — What Did the Federal Circuit Do?
Blog August 17, 2018
En Banc Federal Circuit: Patentee's Service of Complaint, Followed by Voluntary Dismissal, Triggers IPR Clock
Blog October 5, 2017
Legal Alert: Federal Circuit Faults PTO's Approach to Claim Amendments During IPR, But Allows PTO to Try to Fix the Problem
Blog May 16, 2016
Software Claims Directed to Specific Improvements in Computer Operations May be "Non-Abstract"
Blog May 2, 2016
Corporate Residence Definition in Patent Cases Unchanged by Congressional Revisions to Venue Statute; Minimum Contacts Under Beverly Hills Fan Reaffirmed
Blog April 11, 2016
Claims Directed to Detection of Gene Variants Patent-Ineligible, Notwithstanding Mental Activity Requirement
Blog July 8, 2015
Software Claim Addressing Concepts Long Known in Other Fields and Lacking Other Inventive Concept Is Not Patent Eligible
Blog June 18, 2015
Ordered Method Claim Does Not Bar Partly-Simultaneous Performance of Steps
Blog June 17, 2015
Claims Covering Basic Detection of Naturally-Occurring Compound, However Scientifically Significant, Not Patent Eligible
Blog December 4, 2023
Amended FRE 702 on Expert Testimony Effective December 1, 2023
Blog December 1, 2023
ITC Monthly Wrap-Up: November 2023
Blog November 27, 2023
Minnesota Patent Litigation Wrap-Up: Q3 2023
Blog November 15, 2023
ITC Monthly Wrap-Up: October 2023
Blog November 9, 2023
Legal Alert: FTC Challenges More Than 100 Patents as Improperly Listed in Orange Book
Blog November 3, 2023
District of Delaware Finds Allergan Patents Invalid for Lack of Written Description and Obviousness-Type Double Patenting in Allergan v. MSN Labs
Blog October 31, 2023
Texas Patent Litigation Monthly Wrap-Up: October 2023
Blog October 30, 2023
District of Delaware Finds Non-Orange Book-Listed Patents Subject to the Same Pleading Standard as Listed Patents in ANDA Infringement Suit
Blog October 11, 2023
ITC Monthly Wrap-Up: September 2023
Blog September 25, 2023
Federal Circuit Evaluates Enablement for Antibody Claims for the First Time Since Amgen v. Sanofi in Baxalta Inc. et al. v. Genentech, Inc.